Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond
It remains a challenge for the effective treatment of neuroinflammatory disease, including multiple sclerosis (MS), stroke, epilepsy, and Alzheimer’s and Parkinson’s disease. The voltage-gated potassium Kv1.3 channel is of interest, which is considered as a novel therapeutic target for treating neur...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-01-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2019.01393/full |
| _version_ | 1818153799698612224 |
|---|---|
| author | Xiaoli Wang Xiaoli Wang Guoyi Li Jingkang Guo Zhiping Zhang Shuzhang Zhang Yudan Zhu Jiwei Cheng Lu Yu Yonghua Ji Yonghua Ji Jie Tao Jie Tao |
| author_facet | Xiaoli Wang Xiaoli Wang Guoyi Li Jingkang Guo Zhiping Zhang Shuzhang Zhang Yudan Zhu Jiwei Cheng Lu Yu Yonghua Ji Yonghua Ji Jie Tao Jie Tao |
| author_sort | Xiaoli Wang |
| collection | DOAJ |
| description | It remains a challenge for the effective treatment of neuroinflammatory disease, including multiple sclerosis (MS), stroke, epilepsy, and Alzheimer’s and Parkinson’s disease. The voltage-gated potassium Kv1.3 channel is of interest, which is considered as a novel therapeutic target for treating neuroinflammatory disorders due to its crucial role in subsets of T lymphocytes as well as microglial cells. Toxic animals, such as sea anemones, scorpions, spiders, snakes, and cone snails, can produce a variety of toxins that act on the Kv1.3 channel. The Stichodactyla helianthus K+ channel blocking toxin (ShK) from the sea anemone S. helianthus is proved as a classical blocker of Kv1.3. One of the synthetic analogs ShK-186, being developed as a therapeutic for autoimmune diseases, has successfully completed first-in-man Phase 1 trials. In addition to addressing the recent progress on the studies underlying the pharmacological characterizations of ShK on MS, the review will also explore the possibility for clinical treatment of ShK-like Kv1.3 blocking polypeptides on other neuroinflammatory diseases. |
| first_indexed | 2024-12-11T14:16:22Z |
| format | Article |
| id | doaj.art-10b0871ac2d44ebd8944e020d015adac |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-11T14:16:22Z |
| publishDate | 2020-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-10b0871ac2d44ebd8944e020d015adac2022-12-22T01:03:07ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2020-01-011310.3389/fnins.2019.01393490644Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and BeyondXiaoli Wang0Xiaoli Wang1Guoyi Li2Jingkang Guo3Zhiping Zhang4Shuzhang Zhang5Yudan Zhu6Jiwei Cheng7Lu Yu8Yonghua Ji9Yonghua Ji10Jie Tao11Jie Tao12Department of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaInstitute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, ChinaDepartment of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaInstitute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, ChinaInstitute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, ChinaInstitute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, ChinaDepartment of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaInstitute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, ChinaXinhua Translational Institute for Cancer Pain, Shanghai, ChinaDepartment of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaPutuo Clinical Medical School, Anhui Medical University, Shanghai, ChinaIt remains a challenge for the effective treatment of neuroinflammatory disease, including multiple sclerosis (MS), stroke, epilepsy, and Alzheimer’s and Parkinson’s disease. The voltage-gated potassium Kv1.3 channel is of interest, which is considered as a novel therapeutic target for treating neuroinflammatory disorders due to its crucial role in subsets of T lymphocytes as well as microglial cells. Toxic animals, such as sea anemones, scorpions, spiders, snakes, and cone snails, can produce a variety of toxins that act on the Kv1.3 channel. The Stichodactyla helianthus K+ channel blocking toxin (ShK) from the sea anemone S. helianthus is proved as a classical blocker of Kv1.3. One of the synthetic analogs ShK-186, being developed as a therapeutic for autoimmune diseases, has successfully completed first-in-man Phase 1 trials. In addition to addressing the recent progress on the studies underlying the pharmacological characterizations of ShK on MS, the review will also explore the possibility for clinical treatment of ShK-like Kv1.3 blocking polypeptides on other neuroinflammatory diseases.https://www.frontiersin.org/article/10.3389/fnins.2019.01393/fullKv1.3ShKneuroinflammatory diseasemultiple sclerosisstrokeepilepsy |
| spellingShingle | Xiaoli Wang Xiaoli Wang Guoyi Li Jingkang Guo Zhiping Zhang Shuzhang Zhang Yudan Zhu Jiwei Cheng Lu Yu Yonghua Ji Yonghua Ji Jie Tao Jie Tao Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond Frontiers in Neuroscience Kv1.3 ShK neuroinflammatory disease multiple sclerosis stroke epilepsy |
| title | Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond |
| title_full | Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond |
| title_fullStr | Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond |
| title_full_unstemmed | Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond |
| title_short | Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond |
| title_sort | kv1 3 channel as a key therapeutic target for neuroinflammatory diseases state of the art and beyond |
| topic | Kv1.3 ShK neuroinflammatory disease multiple sclerosis stroke epilepsy |
| url | https://www.frontiersin.org/article/10.3389/fnins.2019.01393/full |
| work_keys_str_mv | AT xiaoliwang kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT xiaoliwang kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT guoyili kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT jingkangguo kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT zhipingzhang kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT shuzhangzhang kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT yudanzhu kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT jiweicheng kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT luyu kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT yonghuaji kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT yonghuaji kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT jietao kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond AT jietao kv13channelasakeytherapeutictargetforneuroinflammatorydiseasesstateoftheartandbeyond |